Navigation Links
TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
Date:2/14/2008

- Plan Also Calls for Expansion of Business Development, Streamlining of

Operations -

- Company to Host Conference Call/Webcast at 11 a.m. EST Today -

LA JOLLA, Calif., Feb. 14 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced a strategic plan for 2008 with a focus on clinical development activities to maximize the value of the company's versatile lead compounds: AMPA/kainate receptor antagonists tezampanel and NGX426 and muscarinic agonist NGX267. The plan also calls for the expansion of business development initiatives to evaluate partnership opportunities across the company's product pipeline and the streamlining of operations through an expense-reduction program.

Specifically, the company intends to:

Maximize Value of Versatile Lead Compounds

AMPA/kainate receptor antagonists

-- Conduct a Clinical Guidance meeting with the U.S. Food and Drug

Administration (FDA) in the first half of the year to discuss the

efficacy results from the recently completed Phase II clinical

trial of tezampanel in acute migraine headache. As reported last

October, tezampanel met its primary endpoint of headache pain

relief in a double-blind, placebo-controlled, Phase IIb trial in

306 patients with acute migraine. Depending on the outcome of the

meeting, the company intends to conduct an end-of-Phase II meeting

with the FDA in the second half of 2008.

-- Initiate a Phase II trial of tezampanel in muscle spasticity and

rigidity secondary to spinal cord trauma in the second half of the

year. This trial will b
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
2. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
3. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
4. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
5. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
8. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
9. ImaRx Therapeutics Transitions Business Strategy
10. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
11. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 2, 2015  Only a quarter of physicians ... the patients they prescribe them to, according to new ... of Medicine (BUSM) and myCME , Haymarket ... Daniel Alford, M.D. , director of BUSM,s Safe ... , said, "This indicates a critical need for provider ...
(Date:6/2/2015)... , June 2, 2015  ErgoNurse, the leader in ... of healthcare products in the United States ... nursing home, long-term care and skilled nursing markets. ... ... able to fully take advantage of the ErgoNurse products to ...
(Date:6/2/2015)...  CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical ... that it has reached an agreement to settle the ... Court of Chancery, which names as defendants ... and officers, and names the Company as a nominal ... CytRx Corp. Stockholder Derivative Litigation , C.A. No. 9864-VCL, ...
Breaking Medicine Technology:Survey Results Show Few Doctors Are Very Confident Managing Patients on Opioids 2ErgoNurse and Briggs Healthcare Positioned to Completely Eliminate the Unnecessary Cost of Healthcare-Related Back Injuries 2CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 2CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 3CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 4
(Date:6/2/2015)... Though almost the entire Park family was born ... rule their lives. Organizing and hosting the June 14 event ... to the fullest and spreading awareness of HHT. , “I've ... won't live my life in a bubble because something bad ... is to look back on your life with regret because ...
(Date:6/2/2015)... 02, 2015 Vancouver, BC – ... Research ( http://www.idataresearch.com ), the bone graft substitute ... matrices (DBM) over traditional allograft materials. Because the ... thus an increase in operation time, alternative graft ... growth in these synthetic materials is partly the ...
(Date:6/2/2015)... Recent findings from the 2014 National Youth ... a reduction in conventional cigarette smoking, use of electronic ... has doubled among today’s teens in a year. ... national trend is consistent with what is occurring locally, ... to fully determine the long-term effects of e-cigarette usage ...
(Date:6/2/2015)... PhishLine, LLC today announced it ... Drive, Suite 125 in Waukesha, Wisconsin 53186. ... base of operations for PhishLine’s current corporate staff ... , Mark Chapman, Founder and President, commented “PhishLine ... enterprise customers adopt our market leading service to ...
(Date:6/2/2015)... 2015 Mercy Health (formerly Catholic Health ... Kentucky – has devoted the seventh of its monthly ... cancer prevention. One in five Americans will get skin ... YouTube channel, a Mercy Health expert addresses these skin ... causes of skin cancer? ,     What are the ...
Breaking Medicine News(10 mins):Health News:Family brings awareness to genetic disease at first Memphis walk 2Health News:Medtronic, DePuy Synthes Shift U.S. Bone Graft Substitute Market Towards Synthetic Demineralized Bone Matrices 2Health News:Medtronic, DePuy Synthes Shift U.S. Bone Graft Substitute Market Towards Synthetic Demineralized Bone Matrices 3Health News:Susquehanna Health Pediatrician Warns of Adverse Effects of Teen E-Cigarette Usage 2Health News:Susquehanna Health Pediatrician Warns of Adverse Effects of Teen E-Cigarette Usage 3Health News:PhishLine, LLC Announces New Corporate Headquarters 2Health News:Video provides helpful information about skin cancer prevention 2
... constipation are more likely to get diagnosed with the progressive ... have// some effect on the function of the gut long ... led the research, said: "It could help us more effectively ... high risk of developing the disease in the future." The ...
... type of childhood brain cancer has a unique molecule ... fight it.// Armed with targeted molecular treatments, doctors may ... side effects of prolonged and powerful radiation and chemotherapy ... a collaborative effort looking at a type of childhood ...
... A new invenvtion in the medical history. A team of ... a 68-year old woman using a remote controlled robot. This ... medical history. The operation took place at the European Institute ... it is a phenomenal step and we cannot even begin ...
... the Institute of Health Sciences in Oxford found that women ... to have a stillbirth, or to develop pre-eclampsia.// Taking low-dose ... researchers. ,The researchers reviewed more than 23 previous ... of anti-platelet drugs, of which low-dose aspirin is the most ...
... errors in the alpha gene are the cause of premature ... affects about 2% of the total population.// ,The University ... development of a genetic test, which would allow women with ... are at risk. They analysed DNA from women who had ...
... and marketing rights of the anti-anthrax vaccine developed by the ... is expected that the vaccine would be in the market ... to JNU for the exclusive rights. In addition, it will ... is yet to make any projections on the business the ...
Cached Medicine News:
... is a solid solution for ... package includes the Vibratome Plus, ... blocks, v-block adapter, specimen mounts ... stage assembly for ease in ...
... Vibratome Semi-Automatic Tissue Sectioning System has maintained ... sectioning system. Researchers from around the globe ... for their fresh and fresh fixed tissue ... With the Vibratome Automatic Tissue Sectioning ...
... The NEW Vibratome 3000 Plus Sectioning ... fresh or fixed, animal, or plant tissues. ... principle which allows sectioning without freezing or ... alteration of morphology, the destruction of enzyme ...
... NEW Vibratome 3000 Plus Sectioning System provides ... fixed, animal, or plant tissues. The ... allows sectioning without freezing or embedding. ... morphology, the destruction of enzyme activities, and ...
Medicine Products: